Pfizer announced on Tuesday it will allow low and middle-income countries to make and distribute the company’s COVID-19 pill inexpensively. The move is an attempt to increase the global supply in 95 poorer nations.While the deal helps treat patients, the company has not made the same decision when it comes to its COVID-19 vaccine.Axios Re:Cap host Felix Salmon is joined by Axios health care business reporter Bob Herman to discuss Pfizer’s decisions and the global ramifications.

Pfizer announced on Tuesday it will allow low and middle-income countries to make and distribute the company’s COVID-19 pill inexpensively. The move is an attempt to increase the global supply in 95 poorer nations.While the deal helps treat patients, the company has not made the same decision when it comes to its COVID-19 vaccine. Axios Re:Cap host Felix Salmon is joined by Axios health care business reporter Bob Herman to discuss Pfizer’s decisions and the global ramifications.

Pfizer announced on Tuesday it will allow low and middle-income countries to make and&nbsp;distribute the company’s COVID-19 pill inexpensively. The move is an attempt to increase the global supply in 95 poorer nations.While the deal helps treat patients, the company has not made the same decision when it comes to its&nbsp;COVID-19 vaccine.Axios Re:Cap host Felix Salmon is joined by Axios health care business reporter Bob Herman to discuss Pfizer’s decisions and the global ramifications.

Pfizer agrees to licensing deal for COVID-19 pill

Each weekday afternoon, Axios unpacks the biggest story of the day and why it matters. We'll take you inside the accelerating forces, technologies and trends that are remaking your world and work. About Axios: Axios is a digital media company launched in 2017. Axios - which means “worthy” in Greek - helps you become smarter, faster with news and information across politics, tech, business, media, science and the world. Subscribe to our newsletters at axios.com/newsletters and download our mobile app at axios.com/app. 

Axios Re:Cap is on hiatus until October 2021.

News

Daily News

Each weekday afternoon, Axios unpacks the biggest story of the day and why it matters. We'll take you inside the accelerating forces, technologies and trends that are remaking your world and work. About Axios: Axios is a digital media company launched in 2017. Axios - which means “worthy” in Greek - helps you become smarter, faster with news and information across politics, tech, business, media, science and the world. Subscribe to our newsletters at axios.com/newsletters and download our mobile app at axios.com/app. Axios Re:Cap is on hiatus until October 2021.

Each weekday afternoon, Axios unpacks the biggest story of the day and why it matters. We'll take you inside the accelerating forces, technologies and trends that are remaking your world and work. About Axios: Axios is a digital media company launched in 2017. Axios - which means “worthy” in Greek - helps you become smarter, faster with news and information across politics, tech, business, media, science and the world. Subscribe to our newsletters at axios.com/newsletters and download our mobile app at axios.com/app.&nbsp;

Axios Re:Cap is on hiatus until October 2021.

Share Pfizer agrees to licensing deal for COVID-19 pill

Sign up to save your podcasts

Pfizer agrees to licensing deal for COVID-19 pill

Pfizer agrees to licensing deal for COVID-19 pill

More shows like Axios Re:Cap

On Point | Podcast

Economist Podcasts

Marketplace

Freakonomics Radio

The Conversation with Dasha Burns

The Playbook Podcast

The Daily

Radio Atlantic

Interesting Times with Ross Douthat

1 big thing

Hard Fork

The Ezra Klein Show

How It Happened

Honestly with Bari Weiss

The Weekly Show with Jon Stewart

The Interview

The Opinions